Category Archives: Genetics

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Read more here:
Can genetics be part of the ADHD puzzle? - Southernminn.com

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Trigall Genetics, the world leader in transgenic wheat, and S&W Seed Company (Nasdaq: SANW), a leading middle-market agricultural company, have entered preliminary, nonbinding discussions to potentially combine wheat operations through the creation of Trigall Australia, a wheat breeding company. The combination would harness S&W's Australian footprint and the capabilities of both Bioceres Crop Solutions (Nasdaq: BIOX) and Florimond Desprez, co-owners of Trigall Genetics.

Trigall Genetics is the world leader in transgenic wheat thanks to the development of its drought-tolerance HB4 EcoWheat technology and a leader in conventional wheat breeding in Argentina. Trigall Genetics aims to expand its activities into regions where farmers face climate change challenges and, more specifically, drought. With a harvest of more than 32 million tons of wheat, Australia is a priority development geography for Trigall Genetics, where the effects of climate change are ever more pressing.

S&W Seed Company currently conducts wheat breeding activities in Australia, counting wheat within its crop portfolio alongside sorghum, alfalfa, and various pasture crops. To ensure the most successful development of its wheat variety portfolio, S&W seeks to benefit from the expertise of an international wheat breeder such as Florimond Desprez. Florimond Desprez historically breeds wheat in Greater Europe, North Africa, and Latin America.

Trigall Australia activities would be based in New South Wales and would aim first at developing wheat varieties for all Australian regions and uses, all the while supporting Australian cereal farmers. Trigall Australia would be expected to be the favoured platform for Bioceres Crop Solutions and Florimond Desprez to develop their activities in Australia, be it crop productivity solutions or alternative breeding activities for crops such as barley, durum wheat, potato, or pulses. All Australian wheat breeding activities of S&W would be owned and operated by Trigall Australia.

Franois Desprez, president of Trigall Genetics and Florimond Desprez declares: "As a cereals and pulses breeder, we are very excited with this opportunity which could potentially allow us to step into a major wheat country in the world and reinforces the fruitful cooperation that exists between Bioceres Crop Solutions and Florimond Desprez since 2013."

Federico Trucco, vice-president of Trigall Genetics and CEO of Bioceres Crop Solutions comments: "This investment would be a very important step in our strategy to bring HB4 EcoWheat to farmers in every corner of the world. Australia is not only a leading participant of the global wheat value chain, but it is also a geography that is chronically affected by severe drought events, a condition we seek to mitigate with our drought tolerance technology. Partnering with S&W would allow us to make this opportunity a near-term reality."

Mark Wong, CEO of S&W Seed comments: "We believe this joint venture could significantly strengthen S&W's position in wheat, enabling us to benefit from the worldwide exposure the combined entity provides. Further, it would allow us to focus our efforts internally on our key centers of value. We look forward to further exploring the benefits this unique partnership would enable."

Read more:
S&W Seed (SANW) and Trigall Genetics Enter Discussions to Combine Wheat Efforts in Australia - StreetInsider.com

In a new study, experts report that a boost in the number of pink pigeons in recent decades will not be enough to save the species from a high risk of extinction.

An international team of researchers led by the University of East Anglia worked with organizations in Mauritius to investigate the impacts of what ultimately became a genetic bottleneck across the wild population of pink pigeons.

Across Mauritius, an island nation in the Indian Ocean, there was a rapid collapse in numbers of the pink pigeon in the late 1980s. The decline worsened until there were only 12 birds surviving in the wild.

Since then, conservation efforts by the Mauritian Wildlife Foundation, the Durrell Wildlife Conservation Trust, and the Government of Mauritius National Parks and Conservation Service paid off. The number of wild pink pigeons reached around 500 birds.

The experts analyzed genetic samples that were collected from 175 pink pigeons over nearly two decades, as conservation efforts took place. Based on the analysis of the DNA, the experts found some disappointing news.

The researchers discovered that, despite an increase in population, the pink pigeon now has a high genetic load of bad mutations. They explained that these mutations put the birds at considerable risk of extinction in the wild within 100 years without continued conservation actions.

By studying the genome of a recovered species that was once critically endangered, we can learn how to help other species to bounce back from a population collapse, said study co-lead author Professor Cock van Oosterhout.

During the pigeons population bottleneck, the gene pool lost a lot of variation, and many bad mutations increased in frequency. This genetic load still poses a severe threat, even though the population has recovered in numbers.

The problem is that all individuals are somehow related to each other. They are the descendants of the few ancestors that managed to survive the bottleneck. Hence, it becomes virtually impossible to stop inbreeding, and this exposes these bad mutations. In turn, this can increase the mortality rate, and it could cause the population to collapse again.

The researchers warn that genetic rescue is needed to recover lost genetic variation caused by inbreeding and to reduce the effects of the harmful mutations. This could be achieved by releasing captive-bred birds from UK and EU zoos, they said.

A captive population of pink pigeons in the Gerald Durrell Endemic Wildlife Sanctuary in Mauritius, jointly managed by the Mauritian Wildlife Foundation and the National Parks and Conservation Service, was established in the 1970s, said Professor Jim Groombridge from the University of Kent.

This was used to breed birds for release into the wild, which boosted population numbers. The team also restored habitat by controlling introduced species and provided supplementary food as part of a field programme of intensive conservation management, which further increased the free-living population.

We didnt know how many bad mutations the population carried initially, before the bottleneck, said co-author Dr. Hernan Morales from University of Copenhagen. We first had to simulate the ancestral population to find out how many bad mutations could have evolved. We then checked this data with data on inbreeding depression data from zoo populations of the pink pigeon.

The researchers compared pedigree and fitness data to that of more than 1,000 birds at the Jersey Zoo. The analysis showed that the pink pigeon carried a high genetic load of 15 lethal equivalents.

The computer simulations clearly show that just boosting numbers isnt enough, said Dr. Morales. The population also needs genetic rescue from more genetically diverse birds bred in European zoos. These birds are not as closely related, and they can help to reduce the level of inbreeding. However, there is a risk that we could introduce other bad mutations from the zoo population into the wild.

According to study co-author Sam Speak, the team is now analyzing the genome of the pink pigeon from zoo populations in the UK, trying to locate these bad mutations. We can do this now using bioinformatics tools developed for studying human genetics and the genomes of other model bird species such as the chicken.

By using conservation genomics, future reintroduction programmes can avoid releasing individuals with high genetic load, said Speak. This would help reduce inbreeding and improve the long-term recovery of threatened species such as the pink pigeon.

The study is published in the journal Conservation Biology.

By Chrissy Sexton, Earth.com Staff Writer

View post:
Pink pigeons need a "genetic rescue" to survive extinction - Earth.com

Enlarge / In the case of the samoyed, selection for physical characteristics produced a dog that sure looks happy.

Many dog breeds are purely about appearancethink poodles and the Pekingese. But plenty of other breeds,like racing greyhounds, are devoted to specific tasks. For many of these tasks, physical appearance isn't enough; behavior also matters, like herding by sheepdog breeds or fetching by various retrievers.

It's not surprising that many people ascribe these behaviorsand a wide variety of other, less useful onesto their dog's breed and its underlying genetics. Now, a large team of US-based researchers has looked into whether this belief is accurate. And, with a few exceptions, they find that it's not. With a huge panel of volunteer dog owners, they show that the genetics of dog behavior is built from lots of small, weak influences, and every breed seems to have some members that just don't behave as we expect.

The work is based on a citizen science project called Darwin's Ark. Participants were asked to give details about their dog, including whether it belonged to an established breed (either certified or inferred). They were also asked to fill out short surveys that collectively asked about 117 different behaviors. Overall, they obtained data on some 18,000 dogs, about half of them purebreds.

This information was combined with genetic data, including previously published genome sequences from more than 500 purebred dogs. The researchers of the new study added to the previous data by getting complete genome sequences for 27 mixed-breed dogs, collectively termed "Mendel's mutts." Less thorough genome sequencing was also done on 2,000 additional dogs with owners who filled out the behavioral surveys.

The genetic work showed that, as expected, individual breeds are mostly inbred (the significant exception was the Tibetan mastiff, which is distantly related to most modern dog breeds and was left out of these analyses). Despite the inbreeding, however, there was little in the way of genetic variants that are exclusive to a single breed. Out of nearly 17,000 individual variants tested, only 332 were found in just one breed.

The team found that owners generally knew what their dog's breed was (unless it was a mutt). About 90 percent of the dogs that were certified as belonging to a breed appeared to share 85 percent or more of their DNA with purebred members of that breed. For dogs without certified breeding, this dropped to about 60 percent.

Using this data, the researchers confirmed previously published work showing that many physical traits, like leg length and coat properties, had a clear genetic component.

The researchers looked at the genetics of behavior in two different ways. One was to look at the answers to the individual survey questions and determine if they were associated with any genetic variants. This method had the amusing result that the individual behavior with the strongest genetic association was "gets stuck behind objects," which they narrowed down to a small region that contains a gene associated with cognitive capacity in humans. Howling ended up in a region near a gene involved in human language.

They also clustered the survey questions into groups representing general behavioral tendencies, like the willingness and capacity to follow human instructions, sociability toward other dogs, and desire for human contact. Many of these had a significant genetic component, responsible for 25 percent or more of the differences in behavior for human sociability, toy-directed behavior, and ability and interest to respond to commands. But the effects were generally pretty weak, with mutts only showing about 9 percent of their behavioral tendencies that could be explained by genetic factors.

To determine whether any of these behaviors were connected to specific breeds, the researchers compared the breed/behavior linkage of members of a breed to the same linkage in dogs randomly selected from the entire population. In general, there was not a lot there. Only 5 percent of the breed-behavior combinations were significantly linked, compared to about 40 percent for breed-appearance linkages.

There are a few clear connections, such as border collies (a herding dog) being generally good about following human commands. The problem seems to be that there are exceptions for every behavior. Ninety percent of greyhounds, for example, don't seem to bury their toys, but three of themfrequently did. So, even if a trait does tend to be strongly associated with a specific breed, the breed hasn't been bred for it long enough to fix that behavior completely.

See more here:
Genetics goes to the dogs, finds theres not much to breed behavior - Ars Technica

A University of Alberta researcher researching muscular dystrophy was one of five researchers at the institution to receive a grant from the Heart & Stroke Foundation of Canada.

Toshi Yokota, a professor in the department of medical genetics and current The Friends of Garrett Cumming Research Chair, was a recipient of the 2021-2022 Grant-In-Aid program. This provides funding for important, pertinent, and novel research in the area of heart disease and stroke over three years.

The project funded by the Heart & Stroke Foundation of Canada involves using peptides, short chains of amino acids, to deliver antisense oligonucleotides-shorts, DNA-like molecules, to help with heart failure in patients suffering with muscular dystrophy.

Duchenne muscular dystrophy (DMD), the most common type of muscular dystrophy, is most commonly seen in males, with one in 3,500 males born worldwide suffering from this condition. A person with muscular dystrophy would see progressive weakening of their muscles, such as in their arms and legs and eventually their torso as well.

These patients often do not die from issues with the muscles of their limbs since they can still survive without them; what causes many patients to die in their 20s and 30s is heart failure. Previous methods which have been developed are unable to enter the heart to help with heart failure. Yokota and their team are studying a new molecule which may help with this.

We started this project a couple of years ago and in collaboration with Dr. Hong Moulton, at the Oregon State University, Yokota said. She discovered a new peptide called the DG-9 [and] I found that it works very well in the heart; it penetrates the membrane and we can deliver antisense oligos to the heart muscle.

Yokotas love of research started back when they were a child.

From my elementary school or secondary school I always liked science and I read lots of books about science and I like, for example, watching stars and insects or animals, they said. It sounded quite natural to me. I like science and I like research.

Yokota began diving more into genetics during their undergraduate degree at the University of Tokyo. In graduate school, one of their professors, Dr. Shinichi Takeda, had just started a new lab researching muscular dystrophy and was looking for new students.

I thought genetics was the future of medicine and thats very fascinating I think its quite natural to me to join his lab, they said.

Something that Yokota wants students to remember is to focus on what you can do and what interests you, not what you cannot do.

When I was a high school student I was more interested in astrophysics and read many books written by Stephen Hawking and other scientists, they said. But it turned out I am better at biology and I changed my focus to biology at my university, which worked out very well.

See the rest here:
Heart Warriors: 'Genetics is the future of medicine' according to U of A researcher, who uses it to help with muscular dystrophy - The Gateway Online

Osteoarthritis (OA) is a degenerative joint disease that causes pain and stiffness and decreases mobility. While OA is not always hereditary, experts believe that there may be a genetic component that increases the risk of developing this condition.

Around 32.5 million adults in the United States have OA. Various factors contribute to individuals developing OA, including increasing age, obesity, joint injuries, and a persons sex.

While genetics play a role in increasing the risk of someone developing OA, this condition is not hereditary.

This article explores how genetics contribute to OA and discusses other risk factors.

There are over 100 different types of arthritis, and OA is one of the most common. OA is a degenerative joint disease that worsens over time. Currently, there is no cure for this condition.

When a person has OA, their cartilage breaks down. Cartilage is a protective, fibrous connective tissue that cushions the ends of bones and allows them to move easily over each other.

When cartilage begins to break down, the bones rub against one another. In addition, bony spurs, or osteophytes, might form as the bone attempts to heal itself.

People with OA may experience pain, stiffness, and swelling in the joints.

Autoimmune forms of arthritis, such as rheumatoid arthritis, result from the immune system attacking the bodys healthy tissue.

However, doctors usually consider OA a wear and tear disease, as it is more common in people over the age of 50 and is more likely to affect weight-bearing joints, such as the knees and hips. Injuries or genetic predisposition can also increase the risk of OA.

While OA is not always heredity, in some cases, a person can inherit an increased risk of developing this condition. Experts do not currently know how the predisposition of an increased risk of developing OA passes between family members.

Experts estimate that around 4070% of OA cases have a genetic component, with a stronger link for the hip, hand, and spine. The hereditary forms of OA arise from mutations in genes that help form and maintain bone and cartilage. This type of OA may appear at a young age and rapidly progress.

There is not a single specific gene that increases the risk of developing OA. Multiple genes and other risk factors, such as obesity, injuries, and joint anatomy, also contribute to OA.

Research suggests that several groups of genes may increase the risk of developing OA, including:

While scientists have identified different gene variations that may contribute to OA, they do not yet know precisely what part genetics play in developing this condition.

Additionally, people with certain genetic traits or inheritable conditions, such as Ehlers-Danlos syndrome (EDS), may have an increase in the risk of developing OA.

People with EDS have low collagen levels, which can reduce their ability to support muscles and joints. This can lead to unstable and hypermobile joints that may contribute to OA.

More research is necessary to understand the complex interplay between genetic factors and OA.

The cause of OA is wear and tear at the joints.

A range of factors can contribute to individuals developing OA:

Typically, OA risk increases with age and appears most often in individuals over the age of 50. However, it can appear in younger individuals, particularly after a bone fracture or a cartilage or ligament tear.

OA usually worsens over time and can develop in several joints. It often begins in a single large joint, such as a hip or knee, but it may also involve a smaller joint, such as an ankle.

Some people may have OA in a single joint, but it may progress to involve other joints, such as the spine, neck, and wrists.

While doctors do not fully understand why this happens, it is possible that the pain from OA causes the individual to move differently, which then forces the joints out of alignment.

OA is a degenerative condition with no cure. This condition worsens over time and can cause significant difficulty in mobility.

If a person has individuals in their family with OA, it does not mean they will also develop the condition. Experts estimate that the heritability of OA is around:

Researchers do not fully understand the link between OA and life expectancy. In some cases, OA of the knee or hip may negatively affect an individuals life expectancy, but this is potentially due to pain, difficulty in mobility, and other health conditions.

Other types of OA, such as OA of the hand, do not appear to have an effect on life expectancy.

OA is a degenerative joint disease that worsens over time, causing difficulty in mobility and pain. Age is the primary factor that increases OA risk, but other causes include injury, obesity, sex, and genetics.

The heritability of OA is around 4070%. However, having family members with OA does not mean that a person will develop the condition.

Follow this link:
Is osteoarthritis hereditary? Genetics, causes, and more - Medical News Today

In the unusually muted build-up to the final Old Firm derby of this season, there has been the temptation to bill the meeting as incidental or even inconsequential. There are two reasons for this: with just four games remaining of the Premiership season, Celtic are six points clear of Rangers with a vastly superior goal difference, and Rangers have the small matter of being 90 minutes away from a European final, before RB Leipzigs visit on Thursday.

Celtic can virtually crown themselves champions if they win at Celtic Park today (Sunday) but Rangers could add a bit of pressure to the run-in if they cut the gap to three points.

It would still take a minor miracle for them to retain the title as they would need to take a maximum 12 points from here while hoping Celtic earn five or less in their final three games (Hearts and Motherwell at home, either side of a trip to Dundee United), but out in Dubai there is one man with good reason not to give up hope.

Former Rangers centre-back Madjid Bougherra won the championship in all three of his three seasons at Ibrox between 2008 and 2011, with Rangers twice coming from behind Celtic in the title race to clinch the trophy.

Like many foreign players who immerse themselves in Glasgows footballing tombola after signing for one of the clubs, Bougherra knows what the rivalry means and what the fixture can do to those involved.

He experienced just about every emotion possible from putting four past Celtic, to losing by three, being acrimoniously sent off, involved in heated battles and scoring a crucial winner well, almost.

But when searching for a reason why Giovanni van Bronckhorsts side should not concede defeat in their attempts to retain their domestic crown, he refers back to his 2008-09 debut season, when Gordon Strachans Celtic side looked destined to make it four in a row.

A season that had began with great momentum, including a 4-2 win away to their rivals, had gone off the rails for Rangers after losing against Inverness Caledonian Thistle and then drawing with Hearts in consecutive games. It left Walter Smiths side six point behind Celtic in April; they had a game in hand, but it seemed like they had lost their grip.

Its part of the genetics to be a Glasgow Rangers player that you never give up until the end, says Bougherra, who is now manager of Algeria A the national team compromised of home-based players.

The mentality is to win and win and win. Anything is possible in football, so they need to give everything as the fans will remember that, even if the result doesnt work out.

In that first season, I still believed. We knew it would not come easily but Steven Davis scored (the only goal of a May derby at Ibrox), which meant we won the last derby of the season, and we never looked back.

Davis may well have a part to play this afternoon too, 13 years later. The midfielder, now 37, was a key part of that period along with Bougherra, as Rangers won two of those three titles on the last game of the season away to Dundee United in 2009 and then Kilmarnock two years later.

Maurice Edus stoppage-time winner in a February 2010 derby helped seal their second title, but it was a rebound from Bougherras initial shot. I gave him a kick once we got inside, he laughs.

If Rangers are to pull off a minor miracle in the coming weeks, it will require an even greater Houdini act than when they lost 3-0 to Celtic in February 2011 to fall eight points behind in the race before clawing back the deficit, culminating in an exhilarating 5-1 final day victory away to Kilmarnock.

To win in the last game gave it more charm, more flavour to winning the trophy. When we won against Dundee United (in 2009), I remember the helicopter waiting for us.

You are focused on the game, so you dont hear the helicopter. Sometimes you dont even hear the fans either. The second year we won, it was good as we won with games to spare but it was not as good as the first and third seasons.

In what turned out to be Bougherras final season at the club, the two Glasgow teams played each other no fewer than seven times across the three domestic competitions as the rivalry reached boiling point in March.

Rangers had three men sent off in a 1-0 Scottish Cup last-16 loss at Celtic Park. Bougherra admits the red mist descended as referee Calum Murray gave him a second yellow card in the 93rd minute, and saw him grab the officials wrist to try to prevent Murray ordering him off.

I made a tackle (on Kris Commons) when I was already booked. Ally (McCoist, then Smiths No 2) had been shouting to me to calm down and be careful. I just gave him a wink to say, Its OK, no worries.

It is part of the derby that sometimes you need to be strong and your emotions go up and down with the referee. I was controlling it but the tackle was a very good tackle as I took the ball, not the player. We were losing 1-0 and had a few minutes left so I was not happy to have a second card, as in the derby that tackle is good.

After I was a little nervous, as I didnt want him to give me another yellow. When you are in the game you can lose control, so I went to see him and apologise.

The crazy thing (about Rangers-Celtic matches) is you can play six times, seven times or 10 times and all the players have the same spirit and desire to win. You are never fed up with this game, it is special and you feel the hatred.

I call this a real, real derby. The people are too passionate. The spirit, the noise and the intensity of the game is unique in Europe.

Steven Whittaker was also sent off for two yellows in the first half, as was El Hadji Diouf who spent the season on loan from Blackburn Rovers in a melee after full time.

Diouf and Bougherra produced something of an iconic image as they left Hampden in the week that followed, having had additional bans for their behaviour quashed. So did McCoist for his touchline fracas with Celtic manager Neil Lennon, an incident the Scottish government saw fit to hold a national summit over.

It was a special season as Diouf signed and had some fights with Scott Brown, so there were things that pushed the atmosphere more, Bougherra says. Among these was Diouf mocking Browns celebrations a couple of weeks later after Rangers beat Celtic in the League Cup final.

He just did it himself, laughs Bougherra. Hes a unique player but people dont know him outside of football. I didnt know him before but hes a funny guy and amazing to know. He has a big personality but he is one of those players that when he goes on the pitch he is a different person as he is a winner.

He had a lot of respect for the coaches but I would see Walter smile at him many times in training and its not easy to get a smile from Walter!

This was the type of intensity that Bougherra quickly realised he had to live with if he was to be a success in Glasgow. But only two and a half years before he joined Rangers from Charlton Athletic of the English Championship for 2.5 million it would have seemed far-fetched.

It was a dream to be a footballer, but I was concentrated on my studies in Dijon which was about programming software on computers, Bougherra says of a football journey that began in France in 2002. I was playing in the amateur league on a Sunday mornings but (second-tier club) Gueugnon came to watch me as they were just an hour away.

The first year, it was very hard training every day. I had pain everywhere but my body started changing over time. The second year I was with the first team, and the third year I was playing all the time. But in the fourth year a new coach came in and didnt want me.

I was looking for a loan and had an opportunity in Greece but at the last moment (in the January 2006 window) Crewe Alexandra came in, as they were looking for a centre-back. I was playing for the Algeria Under-23s and an agent was talking about me. We played Port Vale and I played well so I signed and had a fantastic three months (playing 11 games in the Championship).

I had gone from a No 10 to a No 5, so it was easy for me to become a defender as the game was in front of me now, not behind.

His loan at Crewe brought a move to Sheffield Wednesday, also in the Championship, that summer. Six months later, then-Premier League Charlton bought him, but he suffered an injury on his debut against Manchester United at Old Trafford that meant he didnt start again until the final day of the season, by which time the south London club had been relegated.

After a season back in the Championship, Bougherra was all set to join Premier League-bound West Bromwich Albion in the summer of 2008 when he received an 11th-hour phone call from a familiar voice.

My fitness coach at Sheffield Wednesday, Adam Owen (by then working at Ibrox), phoned me and told me to sign for Rangers, he says.

I took a flight during the night and signed in Glasgow the next day. They had just sold Carlos Cuellar (to Aston Villa) for big money so he showed my profile to Walter Smith and decided to take me.

Ally McCoist came to meet me. I felt very comfortable with him. He talks to you as a friend and a brother, so I felt I had signed for a family club.

It had taken until the age of 25 for Bougherra to reach that level but countryman Riyad Mahrez, who he rates as the best he has ever played with, almost joined him in Scottish football after he went on trial to St Mirren the following year as an unknown teenager. Despite scoring seven goals in his trial games, a deal wasnt offered, and the rest is history.

He had a long story before Leicester and Man City, a little bit like me, as it is hard to find a club who trusts you, says Bougherra.

Thats the difficulty, as it sometimes takes time to find the coach who sees something in you. I have many friends who never found that coach to push them higher, so that is the bad side. Football is a little bit like Jenga. You need to survive and never give up.

Bougherra found that coach in Smith, who passed away in November at the age of 73.

Hes a legend. People love him and all the players loved him. In the UK, and especially Glasgow, they respect the people who do good things for the club. Not many places do, so it is amazing. I have no words other than: we miss him.

Smiths impact on Bougherra can be felt in the emotion of the 39-year-olds voice when he speaks.

Walter was very calm due to his experience and he had a big character. Without talking, you respected him and were afraid to miss something, Bougherra says. Ally had our mentality, because he was young he was close to us. So Walter was the big boss and it was the perfect mix.

The first time I saw him very sad, he started shouting in the changing room. Trust me, no one in the dressing room was speaking.

I experienced it too as I had a habit of being five minutes late for training and he put me on the bench after I qualified for the World Cup (in 2010) and came back late.

It was the first time we had qualified in my life, so the atmosphere was amazing and I wanted to stay two days more to enjoy it. I lost my French passport. I had my Algerian one but they needed it for the visa or something.

He was not happy at all. I said sorry and that was the good thing about Walter as when you tell him you are wrong and are sorry, he turns very quickly although he still put me on the bench! I made an assist in the next game, though, so he put me back on the pitch.

Bougherra, whose sturdy physique made him instantly recognisable, says he used to give Rangers kit man Jimmy Bell a headache as he would ask for bigger shorts and shirts, particularly when, one season, the supplied shirts came in a skin-tight fit.

That may have been easier to sell to him during Ramadan, which he is currently observing as he takes a break in Dubai, but Smith was always accommodating when it came to his fasting, and that compassion is what stood out to Bougherra as his greatest quality.

When I had the space, I had the habit to go forward (from centre-back). I gave him a headache! It was my need to run every game. I cannot stay in my position but when I went forward, I came back very fast!

You can find some coaches who change you and the way you play but he used what I have and tried to improve on it, not to take things away from my game. There are too many coaches who try to change a player, but he was different. Tactically, he gave me things to follow every game but he was different.

This is why I felt comfortable with him and why I gave everything for him. He told me, As long as everything you do is for the team and not for yourself, it will be OK.

He gave me that confidence and sometimes I liked to go straight forward or other times I gave the ball to the attacker and keep going to offer a cross. I never remember him saying to stay back once.

Although Bougherras defensive qualities were what helped build a solid foundation alongside David Weir, the freedom he was given in possession is what helped produce two memorable goals, against Dundee United and Stuttgart, as he went on mazy runs before finishing off what were solo strikes any striker would have been proud of.

I was waiting for this one for a long time after about 200 runs, I finally succeeded, he says.

The Stuttgart one was good but I went really far by myself against Dundee United, so that is the best one Ive ever scored.

Bougherra had fellow Algerians Brahim Hemdani and Salim Kerkar as team-mates at Ibrox and the latters role as a cult figure in his two seasons at the club between 2010 and 2012 is what proves his love of the club.

I played with his brother, who was a very good player. Salim was at Gueugnon too when he was young, so I knew him from there, Bougherra says. The club couldnt sign many players as the finances were controlled, so I brought him to the coach for a trial.

Kerkar was signed and, despite only making a handful of starts in cup competitions, was regularly cheered like a hero while warming up.

This is why I love the fans in Glasgow, as small things can be turned into funny or lovely things. I was happy as he helped us in some situations and was like my smaller brother.

Bougherra left Rangers the season before the club imploded to join the Lekhwiya club in Qatar, but says if hed had his way, he would have stayed longer.

I was close to signing for four more years, but the financial situation meant that the offer from Qatar gave them (Rangers) money, he says.

Rangers was the highlight of my career there and I could not have found better anywhere. I didnt know what the competitive mentality was before I joined Rangers but I learned how to win not just one game but to become a winner.

(Top photo: Craig Halkett/PA Images via Getty Images)

Read the original:
Madjid Bougherra interview: Its part of the genetics to be a Rangers player that you never give up until the end - The Athletic

Preimplantation genetic diagnosis (PGD) also referred as embryo screening, is a branch of genetics involves in genetic testing of embryo through in-vitro fertilization (IVF). PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal, or hereditary disorders such as spinal muscular atrophy and cystic fibrosis.

The global PGD market size is estimated to be $79.5 million in 2015 and expected to reach $121.5 million registering a CAGR of 6.14% from 2016 to 2022. The global PGD market is expected to witness notable growth in the near future owing to the rise in prevalence of genetic, hereditary, and chromosomal diseases.

Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=26956

Market Statistics:

The file offers market sizing and forecast throughout 5 primary currencies USD, EUR GBP, JPY, and AUD. It helps corporation leaders make higher choices when foreign money change records are available with ease. In this report, the years 2020 and 2021 are regarded as historic years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2030 are viewed as the forecast period.

The Centers for Medicare and Medicaid Services report that US healthcare expenditures grew by 4.6% to US$ 3.8 trillion in 2019, or US$ 11,582 per person, and accounted for 17.7% of GDP. Also, the federal government accounted for 29.0% of the total health expenditures, followed by households (28.4%). State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.

This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the markets future growth.

Moreover, PGD have high chances of conceiving healthy embryos. However, the high costs incurred in the PGD technologies hamper the market growth. Moreover, stringent government regulations and ethical concerns also obstruct the market growth. In the near future, increase is expected in adoption of PGD worldwide owing to its various applications for development of healthy embryo.

The global PGD market is segmented based on the test type and geography. Based on type, the market can be segmented into aneuploidy, chromosomal abnormalities, gender selection, HLA typing, single gene disorder, X-linked diseases, and others (disability, and adult onset disease). Geographically, the market is segmented into North America, Europe, Asia-Pacific and LAMEA.

Get a Request Sample Report:https://reportocean.com/industry-verticals/sample-request?report_id=26956

The key market players areReprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., and Reproductive Genetics Innovations LLC.

KEY MARKET BENEFITS:

In-depth study of the global preimplantation genetic diagnostic market was conducted based on current testing trends of genetic test and based on the preferences for designer babiesPotential analysis of opportunities was evaluated for understanding different aspects of preimplantation genetic test that are currently under various phases of clinical trials along with the variants that would gain prominence in the futureA deep analysis of key market dynamics that influence the adoption of PGD tests in the forecast periodAnalysis of volume and vale share analysis of PGD testing at a global and regional levelKey market players are profiled and their strategies are analyzed thoroughly for understanding the various technologies adopted by them for development and production of diagnostic tests for PGD testing

KEY MARKET SEGMENT:

By Test Type

Chromosomal abnormalitiesGender selectionX-linked diseasesAneuploidySingle gene disordersOthers

Request full Report-https://reportocean.com/industry-verticals/sample-request?report_id=26956

By Region

North AmericaEuropeAsia-PacificLAMEA

Table of Content:

Key Questions Answered in the Market Report

How did the COVID-19 pandemic impact the adoption of by various pharmaceutical and life sciences companies? What is the outlook for the impact market during the forecast period 2021-2030? What are the key trends influencing the impact market? How will they influence the market in short-, mid-, and long-term duration? What is the end user perception toward? How is the patent landscape for pharmaceutical quality? Which country/cluster witnessed the highest patent filing from January 2014-June 2021? What are the key factors impacting the impact market? What will be their impact in short-, mid-, and long-term duration? What are the key opportunities areas in the impact market? What is their potential in short-, mid-, and long-term duration? What are the key strategies adopted by companies in the impact market? What are the key application areas of the impact market? Which application is expected to hold the highest growth potential during the forecast period 2021-2030? What is the preferred deployment model for the impact? What is the growth potential of various deployment models present in the market? Who are the key end users of pharmaceutical quality? What is their respective share in the impact market? Which regional market is expected to hold the highest growth potential in the impact market during the forecast period 2021-2030? Which are the key players in the impact market?

Inquire or Share Your Questions If Any Before the Purchasing This Report https://reportocean.com/industry-verticals/sample-request?report_id=26956

About Report Ocean:We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATESTel:+1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com

Excerpt from:
Preimplantation Genetics Diagnosis (PGD) Market Future Growth with Technology and Current Trends 2021 to 2030 Queen Anne and Mangolia News - Queen...

Founded in 2011, SOPHiA GENETICS set out to create a world where every clinician has a multidimensional understanding of diseases by integrating data and sharing insights for the benefit of patients across the globe. What began as a research tool for hospitals and research labs, has since evolved into the SOPHiA DDMPlatform of today a collaborative community of thousands of healthcare specialists. Since launch, the platform has grown exponentially, analyzing 39 to 70 percent more patient profiles year-over-year. It took SOPHiA GENETICS five years to hit the milestone of 500,000 genomic profile analyses and just under two years to double that.

Having facilitated the analysis of one million genomic profiles, the SOPHiA DDMPlatform has been exposed to a highly diverse array of genomic variants needed to continually hone machine learning algorithms for the accurate detection of rare and challenging cases. By then sharing these insights, users across the growing SOPHiA DDMCommunity can save time pulling the right signal from the noise to reveal what matters most and help make better-informed decisions for their patients.

Powered by AI and machine learning, the cloud-based SOPHiA DDM Platform was designed to scale, enabling the company to compute more data, support additional data modalities, expand to new geographies, and deploy new applications including added capabilities to longitudinally follow patient's data while being treated for cancer. Since its inception in genomics, the SOPHiA DDMPlatform has evolved to include the analysis of clinical, biological, genomic, and radiomic data to support the numerous ongoing multimodal studies supported by SOPHiA GENETICS. The company is also collaborating with GE Healthcare to advance cancer care by better targeting and matching treatment to a patient's genomic profile and cancer type.

"Since launching our SOPHiA DDMplatform, it has become clear that our vision to bridge science and technology toturn complex multimodal data into valuable insights is resonating among healthcare institutions and their patients globally," said Jurgi Camblong, co-founder and CEO of SOPHiA GENETICS. "They see the value of our collaborative, decentralized platform that breaks down data silos to provide equal access to knowledge and capabilities for the benefit of patients worldwide. I am very proud of this incredible milestone and look forward to the continued growth and diversity of our network."

To learn more about how SOPHiA GENETICS' data-driven insights are improving diagnosis, treatment, and drug development for patients and the larger medical community, visitwww.sophiagenetics.com.

About SOPHiA GENETICSSOPHiA GENETICS (Nasdaq: SOPH) is a health care technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM Platform and related solutions, products and services are currently used by more than 790 hospital, laboratory, and biopharma institutions globally. For more information, visit http://www.sophiagenetics.com, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [emailprotected]to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. . We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

SOURCE SOPHiA GENETICS

Original post:
SOPHiA GENETICS Hits Milestone of One Million Genomic Profiles Analyzed by the SOPHiA DDM Platform USA - English - USA - English - PR Newswire

IT Genetics, a wholly Romanian-owned company and one of the most significant hardware and software solutions providers in the DC/POS (data collection and point of sale) market, is consolidating its position in the foreign market by opening its third international office, this time in Madrid, Spain.

Here, the company markets a wide range of hardware and software solutions required in the digitization process, with broad applicability and proven efficiency in work processes in multiple industries: retail, e-commerce, pharma, manufacturing, logistics, transport, or HoReCa. In addition, IT Genetics Spain offers a wide range of intelligent solutions that can be implemented in the operations of public institutions.

The expansion of the business into Western Europe is a key pillar of the companys development strategy and marks 15 years of IT Genetics.

We chose to take IT Genetics to Madrid because Spain is an intensely digitalized country with a solid entrepreneurial sector that benefits from using our products and solutions. The decision is a strategic one, which comes naturally, as the team in Romania already has a history of working with customers in Spain. With this new opening, we are closer to our partners from Western Europe and can expand our customer portfolio with new companies from the region. said Liviu Sima, co-founder of IT Genetics.

In Spain, IT Genetics operates through itgstore.es, an intuitive e-commerce platform with a user-friendly interface tailored to customer needs. Thus, through IT Genetics, the Spanish business sector will be able to implement some of the most innovative automation solutions offered by world-renowned manufacturers Zebra, Honeywell, Citizen, Hewlett Packard, and Datalogic.

IT Genetics has invested more than 300,000 in its Spanish representative office, with funds predominantly allocated to developing the e-commerce platform. Thanks to the exposure to the digitization and the maturity of the Spanish market, IT Genetics representatives expect to reach a turnover of 2,000,000 euros for Spain in the next three years.

IT Genetics expects to reach sales of 12,000,000 in 2022

In 2021, IT Genetics reached the 10,000,000 turnover threshold, increasing 43% compared to the previous year. These financial results were driven by expanding the product portfolio dedicated to industrial processes and the development of automation solutions using robots.

The results achieved in 2021 demonstrate our teams experience and ability to understand and respond promptly to challenges, even in a context marked by uncertainty and permanent change. With the expansion of our business into Spain, our forecasts for 2022 are more ambitious, and we expect to maintain this upward trend, says Adriana Arhire, CEO of IT Genetics.

See the rest here:
IT Genetics expands its operations in Western Europe by opening a new office in Madrid, Spain - Business Review - Business Review